A multi-center, randomized, double-blind, placebo controlled, parallel evaluation of the efficacy and safety of a new drug in the treatment of the signs and symptoms of benign prostatic hyperplasia.

Trial Profile

A multi-center, randomized, double-blind, placebo controlled, parallel evaluation of the efficacy and safety of a new drug in the treatment of the signs and symptoms of benign prostatic hyperplasia.

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Mar 2014

At a glance

  • Drugs Silodosin (Primary)
  • Indications Benign prostatic hyperplasia
  • Focus Registrational; Therapeutic Use
  • Sponsors Actavis Inc
  • Most Recent Events

    • 01 Mar 2014 Results from a pooled analysis published in the BJU International.
    • 01 Jun 2011 Results published in Prostate Cancer and Prostatic Diseases.
    • 22 Dec 2009 Actual patient number changed from 460 to 462 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top